Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that Eli Lilly's Strattera will face low or nonexistent reimbursement from HMO pharmacy directors for the treatment of Attention- Deficit/Hyperactivity Disorder (ADHD). Despite the low level of reimbursement, psychiatrists and primary care physicians (PCPs) anticipate switching 25% of their patients from psychostimulants to Strattera in the near future, while pediatricians predict switching 10% of their patients. The new PhysicianForum report, entitled Impact of Strattera's Launch and Psychostimulant Patent Expiries, surveyed 16 pharmacy directors of HMOs, 43 PCPs, 36 pediatricians, and 20 psychiatrists about their future prescribing habits and expectations for this arena.
Even though Strattera is a new drug on the market (approved on January 14, 2003), its impact has already been felt. The majority of surveyed physicians report that they have already prescribed this product. However, of the 16 pharmacy directors at HMOs, only one reports that a reimbursement decision for Strattera has been rendered. The remaining directors predict that reimbursement for Strattera will be low, if reimbursed at all.
"Because of strict regulations, the prescription of psychostimulants-- previously the only approved therapies for ADHD--is inconvenient for health care providers," said Christine Blazynski, Ph.D., director, Decision Resources. "However, Strattera is a more desirable therapy for patients, in particular school-age patients, because it is dosed once-daily (eliminating the need for a school nurse to administer the medication in the middle of the school day) and prescriptions can be renewed over the phone."
About the Disease--ADHD
ADHD is one of the most common childhood psychiatric disorders in the United States, and is increasingly recognized as a chronic disease which persists into and throughout adulthood. Acceptance of ADHD as a disorder by both health care professionals and the general public is increasing. Likewise, recognition of symptoms in the adult population will further drive increases in the ADHD market.
PhysicianForum is a new primary research service from Decision Resources. The service offers access to high-volume prescribing PCPs, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and implications for the pharmaceutical market.
About Decision Resources
Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 firstname.lastname@example.org
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall for Decision Resources, +1-781-296-2563,
Web site: http://www.decisionresources.com/